Disc Medicine's Bitopertin Approval Delayed, Stock Drops
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Source: stocktwits
Disc Medicine Inc's stock fell by 7.72% as it crossed below the 5-day SMA, reflecting investor concerns following the FDA's delay in approving Bitopertin, now rescheduled for February 10.
The delay in the approval of Bitopertin, which targets Erythropoietic Protoporphyria, is attributed to safety and efficacy concerns raised by the FDA. This postponement has led to a significant drop in stock price, highlighting the market's reaction to the uncertainty surrounding the drug's launch. Additionally, the company has been preparing for commercialization, but this setback may impact its market readiness and investor confidence.
The implications of this delay could be substantial for Disc Medicine, as it not only affects the anticipated revenue from Bitopertin but also raises questions about the company's overall strategy and market position in the competitive biopharmaceutical landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRON
Wall Street analysts forecast IRON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 77.010
Low
100.00
Averages
120.20
High
154.00
Current: 77.010
Low
100.00
Averages
120.20
High
154.00
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for possibly issuing misleading business information, and investors may be entitled to compensation without any out-of-pocket costs.
- FDA Denial of NDA: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in the new drug application prevented approval, resulting in a 22% drop in stock price on the same day, indicating market concerns about the company's product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, which could impact Disc Medicine's reputation and future financing capabilities as it faces legal scrutiny.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise, which may encourage more investors to join the lawsuit.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing misleading business information, allowing affected shareholders to seek compensation without upfront costs.
- FDA Denial of NDA: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in the new drug application led to its rejection, causing the stock price to plummet by 22% on the same day, indicating significant market concerns about the company's prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, encouraging affected investors to join through their website or by phone, demonstrating the firm's commitment to protecting investor rights.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and successful track record in this field.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ:IRON) due to allegations of materially misleading business information, indicating legal risks that could affect shareholder returns.
- FDA Application Rejection: On February 13, 2026, the U.S. FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application and citing the need for additional evidence to resolve uncertainties, which led to a 22% drop in the company's stock price on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Disc Medicine, allowing affected investors to seek compensation without any out-of-pocket costs, providing a potential financial recovery opportunity for investors.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and successful track record in securities litigation, thereby enhancing investor confidence in their representation.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for possibly issuing misleading business information, which could expose the company to legal liabilities.
- Stock Price Plunge: On February 13, 2026, Disc Medicine's stock fell 22% following the FDA's Complete Response Letter regarding its new drug application, indicating significant market concerns about the company's future prospects.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing affected investors to seek compensation without any out-of-pocket costs, which could have a substantial impact on the company's financial health.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong track record and expertise in this legal domain.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing misleading business information, indicating significant legal risks that could impact stock price and investor confidence.
- FDA Rejection of NDA: On February 13, 2026, the FDA issued a Complete Response Letter rejecting Disc Medicine's new drug application due to uncertainties requiring additional evidence, resulting in a 22% stock price drop on the same day, reflecting market concerns over the company's product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing affected investors to seek compensation without upfront costs, which may attract more investor attention and increase legal pressure on the company.
- Law Firm's Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise in securities litigation, which may influence the outcome of future lawsuits against Disc Medicine.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine, Inc. (NASDAQ:IRON) shareholders due to allegations of misleading business information, aiming to protect investor rights and seek compensation.
- FDA Response Letter Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating it could not approve the new drug application, resulting in a 22% stock price drop that day, directly impacting investors' financial positions.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing investors to participate in claims without any out-of-pocket costs, demonstrating its commitment to addressing investor losses and providing legal support.
- Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, highlighting its leadership and expertise in the industry.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for possibly issuing misleading business information, and investors may be entitled to compensation without any out-of-pocket costs.
- FDA Denial of NDA: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in the new drug application prevented approval, resulting in a 22% drop in stock price on the same day, indicating market concerns about the company's product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, which could impact Disc Medicine's reputation and future financing capabilities as it faces legal scrutiny.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise, which may encourage more investors to join the lawsuit.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing misleading business information, allowing affected shareholders to seek compensation without upfront costs.
- FDA Denial of NDA: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in the new drug application led to its rejection, causing the stock price to plummet by 22% on the same day, indicating significant market concerns about the company's prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, encouraging affected investors to join through their website or by phone, demonstrating the firm's commitment to protecting investor rights.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and successful track record in this field.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ:IRON) due to allegations of materially misleading business information, indicating legal risks that could affect shareholder returns.
- FDA Application Rejection: On February 13, 2026, the U.S. FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application and citing the need for additional evidence to resolve uncertainties, which led to a 22% drop in the company's stock price on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Disc Medicine, allowing affected investors to seek compensation without any out-of-pocket costs, providing a potential financial recovery opportunity for investors.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and successful track record in securities litigation, thereby enhancing investor confidence in their representation.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for possibly issuing misleading business information, which could expose the company to legal liabilities.
- Stock Price Plunge: On February 13, 2026, Disc Medicine's stock fell 22% following the FDA's Complete Response Letter regarding its new drug application, indicating significant market concerns about the company's future prospects.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing affected investors to seek compensation without any out-of-pocket costs, which could have a substantial impact on the company's financial health.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong track record and expertise in this legal domain.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing misleading business information, indicating significant legal risks that could impact stock price and investor confidence.
- FDA Rejection of NDA: On February 13, 2026, the FDA issued a Complete Response Letter rejecting Disc Medicine's new drug application due to uncertainties requiring additional evidence, resulting in a 22% stock price drop on the same day, reflecting market concerns over the company's product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing affected investors to seek compensation without upfront costs, which may attract more investor attention and increase legal pressure on the company.
- Law Firm's Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise in securities litigation, which may influence the outcome of future lawsuits against Disc Medicine.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine, Inc. (NASDAQ:IRON) shareholders due to allegations of misleading business information, aiming to protect investor rights and seek compensation.
- FDA Response Letter Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating it could not approve the new drug application, resulting in a 22% stock price drop that day, directly impacting investors' financial positions.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing investors to participate in claims without any out-of-pocket costs, demonstrating its commitment to addressing investor losses and providing legal support.
- Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, highlighting its leadership and expertise in the industry.
See More
